The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine

Clinical Therapeutics

Volumn 22, Issue 9, 2000, Pages 1021-1034

  Dossenbach, Martin R K ^a   Beuzen, Jean Noel ^b   Avnon, Moshe ^c   Belmaker, Robert H ^d   Elizur, Avner ^e   Mark, Mordechai ^f   Munitz, Hanan ^g   Schneidman, Michael ^h   Shoshani, David ⁱ   Kratky, Petra ^a   Grundy, Starr Lee ^b   Tollefson, Gary D ^b  

^a Lilly Area Medical Center Vienna   (Austria)

^b ELI LILLY AND COMPANY   (United States)

^c Shaar Menashe Mental Health Center   (Israel)

^d MENTAL HEALTH CENTER   (Israel)

^e ABARBANEL MENTAL HEALTH CENTER   (Israel)

^f MINISTRY OF HEALTH   (Israel)

^g GEHA MENTAL HEALTH CENTER   (Israel)

^h Technion Medical School   (Israel)

ⁱ Eli Lilly Israel   (Israel)

Author keywords

Chronic schizophrenia; Clozapine; Olanzapine; Open label; Treatment refractory

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; LEUKOPENIA; MALE; MULTICENTER STUDY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SOMNOLENCE; SUBSTITUTION THERAPY; TARDIVE DYSKINESIA; TREATMENT OUTCOME; URINE INCONTINENCE;

EID: 0033809854     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)80082-X     Document Type: Article

References (40)

1. Treatment of the neuroleptic-nonresponsive schizophrenic patient
2. Biologic indices of heterogenicity in schizophrenia
3. Clozapine for the treatment-resistant schizophrenic. A double blind comparison with chlorpromazine
4. Treatment of neuroleptic-resistant schizophrenic relapse
5. A report of clozapine-induced agranulocytosis in the United States. Incidence and risk factors
6. The pharmacology of olanzapine and if other new antipsychotic agents
7. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats
8. Glutamate receptor dysfunction and schizophrenia
9. Olanzapine increases in vivo dopamine and norepinephrine release in the rat prefrontal cortex, n. accumbens and striatal
10. Clozapine and olanzapine treatment decreases rat cortical and limbic GABA A receptors
11. Atypical antipsychotic drugs selectively increase neurotensin efflux in dopamine terminal regions
12. Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of midbrain dopamine cells
13. The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: Effect of risperidone, prothipendyl, ORG 5222, sertindole and olanzapine
14. The behavioral pharmacology of olanzapine, a novel 'atypical' antipsychotic agent
15. Mechanism of action of atypical antipsychotic drugs: A critical analysis
16. Olanzapine versus haloperidol treatment in first-episode psychosis
17. Depressive signs and symptoms in schizophrenia - A prospective blinded trial of olanzapine and haloperidol
18. Neuropsychological change in early phase schizophrenia over twelve months of treatment with olanzapine, risperidone, or haloperidol
19. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial
20. Olanzapine versus placebo and haloperidol: Acute phase results of the North American Double-Blind Olanzapine Trial
21. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia
22. A blinded, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesias with olanzapine or haloperidol
23. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations
24. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia
25. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia
26. An investigation of subgroup effects in a study of olanzapine vs. clozapine in the treatment of resistant schizophrenic patients
27. Olanzapine in treatment-refractory schizophrenia: Results of an open-label study
28. A rating scale for extrapyramidal side effects
29. A rating scale for drug-induced akathisia
30. Pharmacokinetics and pharmacodynamics of clozapine
31. Olanzapine: A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses
32. Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone
33. The use of olanzapine in non-compliant or treatment-resistant clozapine populations in hospital
34. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
35. Compliance and outcome in patients treated with antipsychotics: The impact of extrapyramidal syndromes
36. Metabolism of clozapine by neutrophils. Possible implications for clozapine-induced agranulocytosis